The association of cardioprotective medications with pneumonia-related outcomes

Albert Wu, Chester Good, John R. Downs, Michael J. Fine, Mary Jo V Pugh, Antonio Anzueto, Eric M. Mortensen

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Introduction: Little research has examined whether cardiovascular medications, other than statins, are associated with improved outcomes after pneumonia. Our aim was to examine the association between the use of beta-blockers, statins, angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs) with pneumonia-related outcomes. Materials and Methods: We conducted a retrospective population-based study on male patients ≥65 years of age hospitalized with pneumonia and who did not have pre-existing cardiac disease. Our primary analyses were multilevel regression models that examined the association between cardiovascular medication classes and either mortality or cardiovascular events. Results: Our cohort included 21,985 patients: 22% died within 90 days of admission, and 22% had a cardiac event within 90 days. The cardiovascular medications studied that were associated with decreased 90-day mortality included: statins (OR 0.70, 95% CI 0.63-0.77), ACE inhibitors (OR 0.82, 95% CI 0.74-0.91), and ARBs (OR 0.58, 95% CI 0.44-0.77). However, none of the medications were significantly associated with decreased cardiovascular events. Discussion: While statins, ACE inhibitors, and ARBs, were associated with decreased mortality, there was no significant association with decreased CV events. These results indicate that this decreased mortality is unlikely due to their potential cardioprotective effects.

Original languageEnglish (US)
Article numbere85797
JournalPloS one
Issue number1
StatePublished - Jan 28 2014

ASJC Scopus subject areas

  • General


Dive into the research topics of 'The association of cardioprotective medications with pneumonia-related outcomes'. Together they form a unique fingerprint.

Cite this